EUCTR2019-004818-34-IE进行中（未招募）1 期
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Men aged 18 years and older, with pathological diagnosis of adenocarcinoma of the prostate.
- •2. EITHER planned for primary RT and judged to be at very high risk for recurrence based on any of the following:
- •- Grade Group 5, OR
- •- Grade Group 4 AND one or more of the following: clinical T2b-4 OR MRI with seminal vesicle invasion OR extracapsular extension OR PSA* > 20ng/mL, OR
- •- Pelvic nodal involvement (involvement of lymph nodes (LNs) at or below the bifurcation of the aorta into the common iliac arteries) defined radiologically as greater than 10mm on short axis using standard CT or MRI, or pathologically confirmed (PSMA PET alone is not considered enough if = 10mm)
- •Post-radical prostatectomy = 365 days prior to randomisation and planned for RT with PSA = 0.1 ng/mL that has risen or remained stable (within = 0.05 ng/mL) since a previous level at least 1 week earlier, judged to be at very high risk for recurrence based on any of the following:
- •- Grade Group 5, OR
- •- Grade Group 4 AND pT3a or higher, OR
- •- Pelvic nodal involvement (involvement of LNs at or below the bifurcation of the aorta into the common iliac arteries) defined radiologically as greater than 10mm on short axis using standard CT or MRI, or pathologically confirmed (PSMA PET alone is not considered enough if = 10mm)
- •* Screening PSA levels are those measured within 240 days prior to randomisation.
- •3. Adequate bone marrow function: Haemoglobin = 100g/L, white cell count (WCC) = 4.0x10^9/L, absolute neutrophil count (ANC) = 1.5x10^9/L and platelets > 100 x 10^9/L
- •4. Adequate liver function: alanine aminotransferase (ALT) < 2 x upper limit of normal (ULN) and total bilirubin < 1.5 x ULN, (or if total bilirubin is between 1.5 - 2 x ULN, they must have a normal conjugated bilirubin)
- •5. Adequate renal function: calculated creatinine clearance > 30 mL/min (Cockroft-Gault)
- •6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
- •7. Study treatment both planned and able to start within 7 days after randomisation
- •8. Willing to complete health-related quality of life (HRQL) questionnaires UNLESS is unable to complete because of literacy or limited vision
- •9. Willing and able to comply with all study requirements, including standard of care treatment such as EBRT, timing and/or nature of required assessments
- •10. Signed, written informed consent
- •Additional:
- •Conventional imaging must be used to confirm eligibility and disease progression, PSMA PET alone is not considered enough.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •11. Prostate cancer with predominant non-adenocarcinoma features(sarcomatoid/spindle cell/neuroendocrine small cell/squamous cell components/other non-adenocarcinoma)
- •12. Involvement of LNs by conventional CT imaging superior to the common iliac artery bifurcation,and/or outside the pelvis(distant LNs).LN involvement is defined by histopathological confirmation,or by a short axis measurement > 10mm on standard imaging(CT or MRI,but not PET).
- •13. Evidence of metastatic disease. Minimum imaging requirements to exclude metastatic disease are defined in the trial protocol.
- •If endocrine therapy (ET)had not started,imaging must be within 60 days prior to randomisation.
- •If ET has been started,radiographic imaging (CT/MRI/CXR)must have been performed no more than 60 days prior to starting ET&no more than 30 days after starting ET &prior to randomisation. Refer to protocol for further detail.
- •14. PSA >100 ng/mL at any time.
- •15. Any prior use of new generation potent AR inhibition(abiraterone,enzalutamide,apalutamide,darolutamide or similar agents).
- •16. Prior endocrine therapy for prostate cancer except for the following,which are allowed:
- •(i)LHRHA and/or(ii)a first-generation nonsteroidal antiandrogen(NSAA)are allowed if commenced no more than 90 days before randomisation.If an NSAA has been used,it must be stopped before starting study treatment with darolutamide/placebo; and
- •Prior use of 5-alpha reductase inhibitor is allowed&if used,it must be stopped before starting study treatment with darolutamide/placebo.
- •17. Bilateral orchidectomy
- •18. Prior pelvic brachytherapy or other radiotherapy that would result in an overlap of radiotherapy fields that would preclude the required RT
- •19. History of
- •Loss of consciousness or transient ischemic attack or stroke within 6 months prior to randomisation,or
- •Significant cardiovascular disease within 6 months prior to randomisation:including myocardial infarction,unstable angina,congestive heart failure(NYHA grade II or greater),ongoing arrhythmias of Grade >2(CTCAE v5.0),thromboembolic events,coronary artery bypass graft.Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
- •20. Known gastrointestinal disease/procedure that could interfere with the oral absorption or tolerance of darolutamide,including difficulty swallowing tablets
- •21. History of another malignancy within 5 years prior to randomisation except for those malignancies treated with curative intent with a predicted risk of relapse of less than 10% including but not limited to non-melanoma carcinoma of the skin;or adequately treated,non-muscle-invasive urothelial carcinoma of the bladder(i.e.Tis, Ta &low grade T1 tumours).
- •All such cases with a history of malignancy within the last 5 years are to be discussed with study team before randomisation. Melanoma in-situ&other adequately treated in-situ neoplasms are not considered malignancies for the purposes of eligibility assessment.
- •22. Concurrent illness,including severe infection that might jeopardise the ability of the participant to undergo the procedures outlined in the protocol with reasonable safety(HIV infection is not an exclusion criterion if it is controlled with anti-retroviral drugs that are unaffected by concomitant darolutamide)
- •23. Presence of any psychological,familial,sociological or geographical condition potentially hampering compliance with the study protocol &follow-up schedule,including alcohol dependence or drug abuse
研究者
相似试验
进行中（未招募）
1 期
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.CTIS2024-514565-18-00Cancer Trials Ireland1,107
进行中（未招募）
3 期
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the ProstateProstate CancerNCT04136353University of Sydney1,100
招募中
1 期
SUrGery with or without dARolutamide in high-risk and/or locally advanced prostate cancerHigh-risk and/or locally advanced prostate cancerMedDRA version: 20.0Level: LLTClassification code: 10001186Term: Adenocarcinoma of prostate Class: 10029104CTIS2022-501518-67-00Institut Claudius Regaud240
进行中（未招募）
2 期
Phase II study of Darolutamide (ODM-201) in patients with androgen receptor-positive salivary gland carcinomaAndrogen receptor-positive salivary gland carcinomaJPRN-jRCT2031190241Tahara Makoto56
进行中（未招募）
1 期
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imagingCastrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).MedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507482-26-00nicancer195